BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting
read more...
Dec 05, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting
read more...
Nov 23, 2016
BeiGene Announces Closing of $200 Million Public Offering
read more...
Nov 17, 2016
BeiGene Announces Pricing of $200 Million Public Offering
read more...
Nov 16, 2016
BeiGene Announces Proposed Public Offering
read more...
Nov 11, 2016
BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting
read more...
Nov 10, 2016
BeiGene Reports Third Quarter 2016 Financial Results
read more...
Nov 03, 2016
BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting
read more...
Nov 01, 2016
BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference
read more...
Oct 07, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia
read more...
Oct 04, 2016
BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9
read more...
Oct 03, 2016
BeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations
read more...
Sep 11, 2016
BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317
read more...
Sep 06, 2016
BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology
read more...
Aug 31, 2016
BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences
read more...
Aug 24, 2016
BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology
read more...
Aug 18, 2016
BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290
read more...
Aug 10, 2016
BeiGene Reports Second Quarter 2016 Financial Results
read more...
Jul 05, 2016
BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China
read more...
Jun 29, 2016
BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317
read more...
